NCT05662241Phase 3Active not recruiting

A Phase 3 Study of Obexelimab in Patients With IgG4-Related Disease

Study sponsor: Zenas BioPharma (USA), LLC

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2025-11-13Actual
Enrollment · participants194Actual
Source updated2026-02-04Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 2 fields changed

Completion date type changed

Before: Estimated. After: Actual.

Primary completion date changed

Before: 15 Nov 2025. After: 13 Nov 2025.

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview